Liminal BioSciences, Inc. is a biopharmaceutical corporation. The company is headquartered in Laval, Quebec and currently employs 487 full-time employees. The firm is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. The company operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP).